At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Brentuximab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Brentuximab vedotin for Relapsed or Refractory Hodgkin Lymphoma and Relapsed or Refractory Anaplastic Large-cell Lymphoma. Completed, enrolled 36 participants across 18 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
CountriesFrance, Germany, Italy, Mexico, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartApr 2012
Primary CompletionOct 2016
Study CompletionApr 2018
TodayJul 2026
First PostedDec 14, 2011
Enrollment StartApr 16, 2012
Primary CompletionOct 12, 2016
Study CompletionApr 12, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 14.5 years ago
Interventions
Brentuximab vedotindrug
Brentuximab vedotin IV infusion